CN105377246B - 针对非酒精性脂肪性肝病(nafld)的新组合物 - Google Patents

针对非酒精性脂肪性肝病(nafld)的新组合物 Download PDF

Info

Publication number
CN105377246B
CN105377246B CN201380075905.9A CN201380075905A CN105377246B CN 105377246 B CN105377246 B CN 105377246B CN 201380075905 A CN201380075905 A CN 201380075905A CN 105377246 B CN105377246 B CN 105377246B
Authority
CN
China
Prior art keywords
use according
sodium
fatty liver
formula
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380075905.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105377246A (zh
Inventor
潘卡杰·帕特尔
亚尼 拉金德拉库马尔·哈里普拉萨德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zadusi Life Sciences Co ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CN105377246A publication Critical patent/CN105377246A/zh
Application granted granted Critical
Publication of CN105377246B publication Critical patent/CN105377246B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380075905.9A 2013-04-22 2013-06-25 针对非酒精性脂肪性肝病(nafld)的新组合物 Active CN105377246B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1468/MUM/2013 2013-04-22
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
IN1468MU2013 IN2013MU01468A (enExample) 2013-04-22 2013-06-25

Publications (2)

Publication Number Publication Date
CN105377246A CN105377246A (zh) 2016-03-02
CN105377246B true CN105377246B (zh) 2018-03-20

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380075905.9A Active CN105377246B (zh) 2013-04-22 2013-06-25 针对非酒精性脂肪性肝病(nafld)的新组合物

Country Status (21)

Country Link
US (3) US20160166539A1 (enExample)
EP (1) EP2988736A1 (enExample)
JP (1) JP6246895B2 (enExample)
KR (1) KR101617812B1 (enExample)
CN (1) CN105377246B (enExample)
AP (1) AP2015008674A0 (enExample)
AU (1) AU2013387996B2 (enExample)
BR (1) BR112015020600A2 (enExample)
CA (1) CA2900435C (enExample)
EA (1) EA201592020A1 (enExample)
GE (1) GEP201706663B (enExample)
HK (1) HK1214968A1 (enExample)
IL (2) IL240183A (enExample)
IN (1) IN2013MU01468A (enExample)
MA (1) MA38385A1 (enExample)
MX (1) MX346943B (enExample)
MY (1) MY180160A (enExample)
PH (1) PH12015501795A1 (enExample)
SG (1) SG11201506218UA (enExample)
UA (1) UA114360C2 (enExample)
WO (1) WO2014174524A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54735B1 (sr) 2011-01-31 2016-10-31 Cadila Healthcare Ltd Tretman za lipodistrofiju
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MA38385A1 (fr) 2013-04-22 2017-09-29 Cadila Healthcare Ltd Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (enExample) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR20180129909A (ko) * 2016-04-22 2018-12-05 타이완제이 파마슈티컬스 컴퍼니 리미티드 (비)알콜성 지방간염 또는 비알콜성 지방간 질환의 치료에 사용하기 위한 날메펜, 날트렉손 또는 이의 유도체
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
SI3600309T1 (sl) 2017-03-28 2022-10-28 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
WO2019071216A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
WO2020128815A1 (en) 2018-12-18 2020-06-25 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
EP4262776A1 (en) * 2020-12-18 2023-10-25 Société des Produits Nestlé S.A. Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558758A (zh) * 2001-07-26 2004-12-29 新的具有降血脂、降血胆固醇活性的吡咯类化合物、其制备方法和含有其的药物组合物及其医药用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
CN1094940C (zh) 1995-04-28 2002-11-27 第一制药株式会社 具有抗肿瘤活性的紫杉酚衍生物
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6130214A (en) 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
CN100357281C (zh) 1998-05-27 2007-12-26 雷迪实验室有限公司 双环化合物、其制备方法和包含它们的药物组合物
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
WO2001053257A2 (en) 2000-01-19 2001-07-26 Cadila Healthcare Ltd. Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
EP2388326A1 (en) * 2005-09-19 2011-11-23 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
KR20090083338A (ko) * 2006-09-18 2009-08-03 알닐람 파마슈티칼스 인코포레이티드 ＳＣＡＰ의 ＲＮＡｉ 조절 및 이들의 치료적 용도
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
US8772342B2 (en) 2009-11-26 2014-07-08 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
RS54735B1 (sr) * 2011-01-31 2016-10-31 Cadila Healthcare Ltd Tretman za lipodistrofiju
MA38385A1 (fr) 2013-04-22 2017-09-29 Cadila Healthcare Ltd Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (enExample) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
IN2013MU02905A (enExample) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558758A (zh) * 2001-07-26 2004-12-29 新的具有降血脂、降血胆固醇活性的吡咯类化合物、其制备方法和含有其的药物组合物及其医药用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
International Nonproprietary Names for Pharmaceutical Substances (INN) Dénominations communes internationales des Substances pharmaceutiques (DCI);ANONYMOUS;《WHO Drug Information》;20120101;第26卷(第4期);第442页 *
PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes;YEON SEOK SEO;《JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY》;20080101;第23卷(第1期);摘要 *
Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis;TERESA RAMIREZ;《JOURNAL OF CLINICAL & EXPERIMENTAL PATHOLOGY》;20120101;第2卷(第4期);摘要 *

Also Published As

Publication number Publication date
US20170087127A1 (en) 2017-03-30
JP2016515608A (ja) 2016-05-30
EA201592020A1 (ru) 2016-05-31
IL240183A0 (en) 2015-09-24
HK1214968A1 (zh) 2016-08-12
EP2988736A1 (en) 2016-03-02
AU2013387996A1 (en) 2015-09-24
AU2013387996B2 (en) 2015-12-10
US20180185330A1 (en) 2018-07-05
PH12015501795A1 (en) 2015-11-09
JP6246895B2 (ja) 2017-12-13
UA114360C2 (uk) 2017-05-25
CA2900435C (en) 2017-02-14
MY180160A (en) 2020-11-23
US9814697B2 (en) 2017-11-14
WO2014174524A1 (en) 2014-10-30
MX2015010769A (es) 2015-11-26
IL247231A (en) 2017-03-30
MA38385A1 (fr) 2017-09-29
AP2015008674A0 (en) 2015-08-31
GEP201706663B (en) 2017-05-10
MX346943B (es) 2017-04-06
BR112015020600A2 (pt) 2017-07-18
CN105377246A (zh) 2016-03-02
CA2900435A1 (en) 2014-10-30
KR101617812B1 (ko) 2016-05-03
KR20150118990A (ko) 2015-10-23
WO2014174524A8 (en) 2015-10-01
IL240183A (en) 2016-08-31
IN2013MU01468A (enExample) 2015-04-17
US20160166539A1 (en) 2016-06-16
SG11201506218UA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
CN105377246B (zh) 针对非酒精性脂肪性肝病(nafld)的新组合物
US12178799B2 (en) Treatment for primary biliary cholangitis
WO2007147297A1 (fr) Utilisation de dérivés de pyridone destinés à prévenir et traiter par radioactivité une lésion des poumons
CN119499252A (zh) 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
TW201343163A (zh) 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
US12201609B2 (en) Saroglitazar for the treatment of hepatocellular carcinoma
US20220175721A1 (en) Treatment for polycystic ovarian syndrome (pcos)
OA17459A (en) A novel composition for nonalcoholic fatty liver disease (NAFLD).
RU2530889C2 (ru) Соединения и составы для доставки активных веществ
HK40009314A (en) Treatment for primary biliary cholangitis
HK40009314B (en) Treatment for primary biliary cholangitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: India, Gujarat

Patentee after: Zadusi Life Sciences Co.,Ltd.

Address before: India, Gujarat

Patentee before: CADILA HEALTHCARE Ltd.